Date:March 21, 2013

Susan Blaney, MD


Executive Vice Chair
Department of Pediatrics
Baylor College of Medicine

Deputy Director
Texas Children’s Cancer and Hematology Centers

Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine

Dr. Susan Blaney
Texas Children’s Cancer Center
1102 Bates Street, Suite 1570.40
Houston, TX 77030

Phone: 832-822-1482
Fax: 832-825-4299

About Susan Blaney, M.D.

Dr. Susan Blaney is the Deputy Director of the Texas Children’s Cancer and Hematology Centers, and Executive Vice Chair of the Department of Pediatrics at Baylor College of Medicine (BCM). She is also the Vice Chair of the Children’s Oncology Group, the National Cancer Institute (NCI) supported clinical trials group and the world’s largest organization devoted exclusively to pediatric cancer research.

Dr. Blaney served as the Co-Director of the Developmental Therapeutics Program at Texas Children’s Cancer Center where she performs pre-clinical and clinical studies of new antineoplastic agents. A primary focus of her research is the development of new drugs for the treatment of central nervous system tumors in children with a particular emphasis on the development of new agents for intrathecal administration.

For more information, visit Dr. Susan Blaney’s profile on VIICTR.


M.D., Medical College of Ohio
Internship, Tripler Army Medical Center
Residency, Letterman Army Medical Center
Fellowship, Walter Reed Army Medical Center

Board Certifications

American Board of Pediatrics
American Board of Pediatrics-Hematology/Oncology

Selected Memberships

Vice Chair, Children’s Oncology Group (COG)
Executive Committee, Children’s Oncology Group (COG)
Scientific Council, Children’s Oncology Group (COG)
Steering and Executive Committee, Pediatric Brain Tumor Consortium (PBTC)
American Society Clinical Oncology (ASCO)
American Association Cancer Research (AACR)
American Society Pediatric Hematology/Oncology (ASPHO)

Clinical Interests

New Drug Development

Research Interests

Pre-clinical and clinical studies of new antineoplastic agents
Developmental Therapeutics
Central nervous system tumors
New agents for intrathecal administration